A Phase 2 Multicenter Single-Arm Clinical Trial of Zanzalintinib and Pembrolizumab in Subjects With Resectable Clear Cell Renal Cell Carcinoma
18h agoen
From the article
Conditions : Patients With Locally Advanced or Metastatic But Resectable Clear Cell Renal Cell Carcinoma Interventions : Drug: Zanzalintinib and Pembrolizumab Sponsors : Yonsei University Not yet recruiting
Continue reading on clinicaltrials.govYou might also wanna read
GlaxoSmithKline submits European marketing authorisation application for Pazopanib in advanced kidney cancer
GSK·17y ago
ClinicalKey
clinicalkey.com·1mo ago
Savolitinib in MET-amplified gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial
doi.org·6d ago
Real-World EV Plus Pembro Success Seen in Urothelial Cancer
Medscape·1d ago
Casdatifan shows durable response linked to HIF-2α biology in kidney cancer
Nature Communications·8d ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.